Search

Your search keyword '"Strauss, V"' showing total 15 results
Start Over Author "Strauss, V" Language undetermined
15 results on '"Strauss, V"'

4. Is there a role for an FDG derived biological boost in squamous cell anal cancer?

Author

Sabbagh, A, Jacobs, C, Cooke, R, Chu, K, Ng, S, Strauss, V, Virdee, P, Hawkins, M, Aznar, M, and Muirhead, R

Subjects
carbohydrates (lipids)
Abstract

Aim We aim to investigate the potential role for a biological boost in anal cancer by assessing whether subvolumes of high FDG avidity, identified at outset, are spatially consistent during a course of chemoradiotherapy (CRT). Methods FDG-PET scans from 21 patients enrolled into the ART study (NCT02145416) were retrospectively analysed. A total of twenty-nine volumes including both primary tumours and involved nodes >2 cm were identified. FDG-PET scans were performed prior to treatment and day 8 or 9 of CRT. FDG subvolumes were created using a percentage of maximum FDG avidity at thresholds of 34%, 40%, 50%, on the pre-treatment scans, and 70% and 80% on the subsequent scans. Both FDG-PET scans were deformably registered to the planning CT scan. The overlap fraction (OF) and vector distance (VD) were calculated to assess spatial consistency. FDG subvolumes for further investigation had OF >0.7, as this has been defined in previous publications as a “good” correlation. Results The median OF between the diagnostic FDG-PET subvolumes 34%, 40% and 50% of max SUV and subsequent FDG-PET subvolumes of 70% of max SUV were 0.97, 0.92 and 0.81. The median OF between the diagnostic FDG-PET subvolumes 34%, 40% and 50% and subsequent FDG-PET subvolumes of 80% were 1.00, 1.00 and 0.92. The median (range) VD values between diagnostic FDG-PET subvolumes 34%, 40% and 50% and subsequent FDG-PET subvolumes of 80% were 0.74mm (0.19-2.94) 0.74mm (0.19-3.39) and 0.71 (0.2-3.29) respectively. Twenty out of 29 volumes (69.0%) achieved a threshold of >0.7 between the FDG 50% subvolume on the diagnostic scan and the FDG 80% subvolume on the subsequent scan. Conclusion FDG avid subvolumes identified at baseline were spatially consistent during a course of CRT treatment. The subvolume of 50% of SUVmax on the pre-treatment scan could be considered as a potential target for dose escalation.

Published
2018

7. SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component

Author

Mukherjee, S, Virdee, P, Shaw, R, Bridgewater, J, Radhakrishna, G, Falk, S, Scott-Brown, M, Strauss, V, Brookes, C, Gillmore, R, Patel, N, Tranter, B, Parsons, P, Sebag-Montefiore, S, Hawkins, M, Corrie, P, and Maughan, T

Abstract

The anti-retroviral agent, nelfinavir, demonstrates radiosensitising effects in pre-clinical models of pancreatic cancer. The primary objective of Stage 1 was to establish the maximum tolerated dose (MTD) of nelfinavir combined with capecitabine-chemoradiation (CRT) after gemcitabine+nab-paclitaxel (GEMABX) induction chemotherapy. Other outcomes included overall survival and progression-free survival.

Published
2018

8. Fine-tuning the assemblies of carbon nanodots and porphyrins

Author

Scharl T., Cadranel A., Haines P., Strauss V., Bernhardt S., Vela S., Atienza C., Gröhn F., Martín N., Guldi D.M. and 'AC acknowledges a DAAD/ALEARG postdoctoral fellowship and is a member of ALN. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) via SFB 953 'Synthetic Carbon Allotropes'. NM acknowledges support from the Spanish Ministry of Economy and Competitiveness (MINECO) (project, CTQ2017-83531-R), Community of Madrid Government (Fotocarbon project S2013/MIT-2841) and the European Research Council (ERC-320441-Chirallcarbon). CA for a Ramón y Cajal fellowship.'

Published
2018

9. P-233: SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer

Author

Virdee, P, Shaw, R, Strauss, V, Hamill, C, Hurt, C, Gwynne, S, Corrie, P, Bridgewater, J, Parsons, P, Tranter, B, Sebag-Montefiore, D, Chu, K, Radhakrishna, G, Hawkins, M, O'Neill, E, Campbell, S, Love, S, Maughan, T, and Mukherjee, S

Abstract

hemotherapy followed by consolidation chemoradiotherapy (CRT) is a treatment option for locally advanced non-metastatic pancreatic cancer (LAPC), but outcome remains poor. The SCALOP trial identified a feasible, safe, and effective CRT regimen for LAPC: capecitabine (830mg/m2 oral bd) as radiosensitisation + 50.4Gy in 28 fractions. The two-stage SCALOP-2 trial aims to improve this regimen by increasing radiotherapy dose intensity and adding nelfinavir as an additional radiosensitising AKT inhibitor.

Published
2017

10. SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer

Author

Virdee, P, Shaw, R, Strauss, V, Hamill, C, Hurt, C, Corrie, P, Bridgewater, J, Parsons, P, Tranter, B, Sebag-Montefiore, D, Chu, K, Radhakrishna, G, Hawkins, M, O'Neill, E, Campbell, S, Love, S, Maughan, T, and Mukherjee, S

Abstract

Chemotherapy followed by consolidation chemoradiotherapy (CRT) is a treatment option for locally advanced non-metastatic pancreatic cancer (LAPC), but outcome remains poor. The SCALOP trial identified a feasible, safe, and effective CRT regimen for LAPC: capecitabine (830mg/m2 oral bd) as radiosensitisation + 50.4Gy in 28 fractions. The two-stage SCALOP-2 trial aims to improve this regimen by increasing radiotherapy dose intensity and adding nelfinavir as an additional radiosensitising AKT inhibitor.

Published
2017

11. The mechanical bond on carbon nanotubes: Diameter-selective functionalization and effects on physical properties

Author

Martínez-Periñán E., De Juan A., Pouillon Y., Schierl C., Strauss V., Martín N., Rubio Á., Guldi D.M., Lorenzo E., Pérez E.M. and 'A. dJ. and E. M. P. gratefully acknowledge funding from the European Research Council MINT (ERC-StG-2012-307609), the Comunidad Aut?noma de Madrid (MAD2D S2013/MIT-3007) and the MINECO of Spain (CTQ2014-60541-P). Y. P. and A. R. acknowledge financial support from the European Research Council (ERC-2010-AdG-267374), Spanish grant (FIS2013-46159-C3-1-P), Grupos Consolidados (IT578-13), and AFOSR Grant No. FA2386-15-1-0006 AOARD 144088, H2020-NMP-2014 project MOSTOPHOS, GA no. SEP-210187476 and COST Action MP1306 (EUSpec), as well as technical and human support provided by IZO-SGI SGIker of UPV/EHU and its European funding (ERDF and ESF). N. M. gratefully acknowledges financial support from the European Research Council ERC-2012-ADG-320441 (Chirallcarbon), MINECO of Spain (project CTQ2014-52045-R), MOLESCO (Grant Number 606728), and CAM (FOTOCARBON Project S2013/MIT-2841). N. M. is indebted to the Alexander von Humboldt Foundation. D. M. G. gratefully acknowledges funding from the Deutsche Forschungsgemeinschaft as part of the Collaborative Research Centre SFB 953 'Synthetic Carbon Allotropes' and of the Excellence Cluster 'Engineering of Advanced Materials'. The Bayerische Staatsregierung is acknowledged for funding granted as part of the 'Solar Technologies go Hybrid' initiative. E. L. is thankful for support by the Comunidad Aut?noma de Madrid (project NANOAVANSENS S2013/MIT-3029) and the Spanish Ministerio de Ciencia e Innovacion (project CTQ2014-53334-C2-1-R).'

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results